Replies to post #112412 on Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

WRONG!
Let's factually and truthfully sum up why many get excited because what Koos is doing to advance and develop the pipeline, Patents, Preclinical trials and more.

15 Mar 2022 Preclinical trials in Myelodysplastic syndromes in USA (IV) (Regen Biopharma pipeline)
10 Mar 2022 Preclinical development in Breast cancer and Myelodysplastic syndrome is ongoing USA

https://adisinsight.springer.com/drugs/800037634

HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
https://seekingalpha.com/news/3861544-regen-biopharma-up-21-three-month-high-after-patent-fill
LoL! I also showed the older successful human study with links that got FDA clearance with patients and the study was successful!
Here it is again!
Successful study:
https://www.prnewswire.com/news-releases/pan-am-cancer-treatment-center-provides-final-hemaxellerate-clinical-data-to-regen-biopharma-inc-for-treatment-of-bone-marrow-suppression-study-598169731.html
FDA clearance:
https://www.prnewswire.com/news-releases/regen-biopharma-inc-receives-fda-clearance-to-initiate-clinical-trial-of-hemaxellerate-562342421.html

RGBP is way ahead of where it was back then with new Patents, & IND’s
past studies and the latest preclinical trial!
1 patent granted in 2022
2 patents granted in 2021
4 more published applications in 2021.
https://www.prnewswire.com/news-releases/regen-biopharma-inc-responds-to-numerous-requests-for-updates-on-its-intellectual-property-ip-portfolio-301504448.html
I can’t wait for the FDA Fast Track! It also Looks like our NR2F6 human patent was finally granted! While some claimed it would never happen LoL!
Patent Grant 11241427
U.S. patent number 11,241,427 [Application Number 15/364,111] was granted by the patent office on 2022-02-08 for small molecule modulators of nr2f6 activity. This patent grant is currently assigned to KCL Therapeutics, Inc.. The grantee listed for this patent is Regen Biopharma, Inc.. Invention is credited to Thomas Ichim, David Koos.
FDA already granted HemaXellerate and human study was successful.
nr26f patent granted
The other IND activation filed is a shoe in IMO!
No if ands or Butts about it.
RGBP has a Dream team of scientific professionals working for team RGBP and it’s not if but when! LoL!
Past human studies where also Successful! LOL!
While some claimed they would never happen or the IND’s would not get approved! LoL!
Latest preclinical trial:
https://adisinsight.springer.com/drugs/800037634
Stay tuned much more on the way!